https://www.selleckchem.com/
Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve outcomes. Idronoxil is a synthetic flavonoid derivative with radiosensitising properties. To evaluate the safety and activity of Lu PSMA 617 (LuPSMA-617) in combination with idronoxil suppositories (NOX66) in patients with end-stage mCRPC. Thirty-two men with progressive mCRPC previously treated with taxane-based chemotherapy (91% treated with both
Respect!
Kommentar
Delen
